Dermaliq Therapeutics Signs USD 15 Million Series A Round to Advance Three Transformative Drug Therapies into Clinical Trials
- Dermaliq Therapeutics, Inc. is an independent private pharmaceutical company emerged from Novaliq
- Spin-off to unlock value in the space of medical dermatology by using Novaliq’s transformative technology outside eye care
- 3E Bioventures Capital and Beijing Whale Technology Corporation Ltd join as new investors
- Proceeds will be used for three Phase 1/2a clinical development programs in dermatology
Novaliq GmbH, 3E Bioventures Capital and Beijing Whale Technology Corporation Ltd. today announced the establishment of Dermaliq Therapeutics, Inc (Dermaliq), a newly formed Delaware-based pharmaceutical development company, and the signing of a USD 15 million Series A financing round. 3E Bioventures Capital, a leading international life science investor, led the round and was joined by Beijing Whale Technology Corporation Ltd. Dermaliq´s existing shareholder Novaliq has transferred, and licensed Intellectual Property (IP) related to the field of dermatology to Dermaliq.